Recombinant protein composition with anti-wrinkle and firming effects and application thereof

Abstract

The invention discloses a recombinant protein composition with anti-wrinkle and firming effects. The recombinant protein composition comprises the following components: elastin, XVII type collagen and fibronectin, the mass ratio of the elastin to the XVII type collagen to the fibronectin is (3-500): (10-250): (15-250). The invention further discloses application of the recombinant protein composition and an anti-wrinkle firming skin care product containing the recombinant protein composition. The recombinant protein composition disclosed by the invention has good anti-wrinkle and tightening effects, and has a remarkable improvement effect on senescence manifestations of epidermis, dermis and dermis-epidermis joints.

Description

Technical Field

[0001] This invention belongs to the field of cosmetic technology, specifically relating to a recombinant protein composition with anti-wrinkle and firming effects and its application. Background Technology

[0002] Collagen is an important structural protein in the skin. It not only maintains skin elasticity and firmness but also preserves the normal mechanical strength of skin tissue. Skin aging is caused by the combined effects of endogenous factors (such as genetics and hormone levels) and exogenous factors (such as photoaging and environmental chemicals). These factors cause the degradation of collagen and elastin in the skin, thus accelerating the aging process. Collagen is a major component of the extracellular matrix (ECM), and research shows that a reduction in the ECM in the dermis (especially collagen) is a major mechanism of skin aging.

[0003] p16, p21, and p53 are important proteins related to cell cycle regulation and aging, playing a crucial role in skin aging. During skin aging, the expression of p16, p21, and p53 increases, leading to decreased skin cell proliferation, cell cycle arrest, cellular senescence, impaired function, and an increased probability of skin cancer. Inhibiting the expression of these aging proteins can help slow down the rate of skin aging.

[0004] The most important function of the dermal-epidermal junction (DEJ) is signal transmission, which relies on the only collagen in the upper half of the hemidesmosome—collagen type XVII (COL17A1). During skin aging, the loss of type XVII collagen leads to premature depletion of epidermal stem cells, slowed epidermal renewal, and decreased barrier function. This weakens the TGF-β / Smad pathway, reduces the expression of type I and III collagen and fibronectin, weakens the inhibition of metalloproteinases and elastase activity, decreases extracellular matrix content, weakens the support of the dermis, and accelerates skin aging.

[0005] In summary, aging of the dermis is characterized by a decrease in mature collagen and the presence of significant basophilic changes in collagen. Increased levels of aging proteins cause degraded elastic fibers to clump together, further deteriorating into amorphous masses composed of disorganized elastic fibroblasts and fiber bundles. The epidermal-dermal junction exhibits decreased structural stability, reduced anchoring fiber function in the DEJ layer, dilated and congested blood vessels in and beneath the dermal papillae, and varying degrees of inflammatory mediator release around the blood vessels; signal transduction and induced synthesis capabilities are also reduced. The epidermis is characterized by thinning, decreased skin hydration, loss of keratinocyte polarity, irregular arrangement, decreased smoothness, roughness, peeling, and accompanying redness and pigmentation.

[0006] Based on the above aging factors, there is a need for a composition that can significantly enhance collagen synthesis and expression, inhibit the expression of aging proteins, promote cell signal transduction, and enhance the epidermal barrier function. When this composition is combined with a cosmetic matrix, a cosmetic product can be made that has the effects of firming and elasticity, reducing fine lines, moisturizing and smoothing, and reducing redness and pigmentation. Summary of the Invention

[0007] The present invention aims to address the above-mentioned technical problems by providing a composition with anti-wrinkle and firming properties, which can effectively enhance collagen synthesis and expression, inhibit the synthesis of aging proteins, improve the skin epidermal condition, and alleviate skin aging problems.

[0008] To achieve the above-mentioned objectives, the present invention provides the following technical solution:

[0009] In a first aspect, the present invention provides a recombinant protein composition with anti-wrinkle and firming effects, the composition comprising the following components: elastin, type XVII collagen, and fibronectin; the mass ratio of elastin, type XVII collagen, and fibronectin is (3-500):(10-250):(15-250).

[0010] Preferably, the mass ratio of elastin, type XVII collagen and fibronectin is (3-100):(10-50):(15-50).

[0011] Preferably, the mass ratio of elastin, type XVII collagen and fibronectin is (1-2):(1-2):(1-2).

[0012] Preferably, the mass ratio of elastin, type XVII collagen, and fibronectin is 2:1:1.

[0013] Elastin is the main component of elastic fibers in biodermal tissue. It is a highly hydrophobic, non-glycosylated fibrous protein. Its peptide chain is rich in proline and glycine, rarely hydroxylated, contains no hydroxylysine, and is unmodified by glycosylation. As a structural protein, elastin provides mechanical strength and properties to tissues, maintains tissue morphology, and imparts tensile strength. Elastin is a very stable protein in the extracellular matrix. Although it only accounts for 2%-4% of the total protein content of the skin, it is crucial for maintaining skin structure. Elastin can combine with microfibrils to form elastic fibers, whose main function is passive stretching and contraction, giving the tissues and organs it resides in elasticity and reversible deformability. As part of the extracellular matrix, it interacts closely with cells within fibrous tissue, participating in physiological processes essential for tissue homeostasis, such as inducing chemotaxis, promoting cell proliferation, promoting collagen and elastin synthesis, and regulating cell differentiation. It thus possesses important biological functions.

[0014] p16 (CDKN2A) is a cell cycle repressor protein that primarily inhibits cell cycle progression by suppressing CDK4 / 6 activity. In skin aging, p16 expression typically increases, leading to decreased skin cell proliferation, damaged skin tissue structure, and accelerated skin aging. p21 (CDKN1A) is also a cell cycle repressor protein that primarily suppresses the cell cycle by inhibiting the CDK complex. p21 expression also increases during skin aging, resulting in cell cycle arrest, cellular senescence, and impaired cellular function. p53 (TP53) is an important tumor suppressor gene that functions in response to cell damage or stress, regulating cellular stress responses, DNA repair, and apoptosis. In the skin, increased p53 activity may be associated with skin aging and skin cancer. With age and environmental factors, p53 activity increases, leading to skin cell aging and an accelerated rate of skin aging. Elastin can regulate the expression of these three aging proteins.

[0015] Type XVII collagen delays skin aging through four core mechanisms: structural support, stem cell regulation, anti-oxidation, and anti-degradation. Its transmembrane properties give it both mechanical anchoring and signal transduction functions. The expression level of Type XVII collagen is closely related to skin rejuvenation, and exogenous supplementation or promotion of its expression may become a new target for anti-aging products.

[0016] Fibronectin is generally composed of two similar subunits. Analysis reveals that each subunit contains several domains. Some of these domains can recognize and bind extracellular matrix components, such as type I, II, and IV collagen, while others can recognize and bind cell surface receptors. Therefore, fibronectin mediates cell adhesion, enhancing both intercellular and cell-extracellular matrix adhesion. Fibronectin helps maintain cell morphology by binding to cell surface receptors and extracellular matrix components such as collagen. Thus, fibronectin acts as a molecular "bridge," anchoring cells to the extracellular matrix and increasing dermal density. Fibronectin also promotes cell migration, effectively facilitating the migration of keratinocytes and fibroblasts to wounds, accelerating wound healing, reducing the expression of inflammatory mediators, blocking sensitive signals, and improving skin barrier function.

[0017] The composition selected in this invention uses elastin to stimulate collagen expression, directly replenishing collagen, inhibiting the synthesis of aging proteins, and replenishing the extracellular matrix in the dermis. Fibronectin stabilizes cell morphology, promotes intercellular adhesion and migration, promotes high expression of skin barrier-related genes, and inhibits sensitivity-related inflammatory factors, thereby achieving the biological function of promoting cell regeneration and repair. Type XVII collagen can promote the expression of DEJ-related proteins, and its unique feedback regulation of signal transduction efficiently induces collagen synthesis in the dermis downwards and promotes stratum corneum proliferation and differentiation upwards, enhancing skin barrier function. In summary, this composition has the ability to address anti-aging and firming effects across the epidermis, dermal-epidermal junction, and dermis. The three components work synergistically and comprehensively target specific areas, achieving full-layer skin firming and anti-aging.

[0018] In a second aspect, the present invention provides the use of the recombinant protein composition in the preparation of products for anti-wrinkle and / or skin firming.

[0019] Thirdly, the present invention provides an anti-wrinkle and firming skin care product comprising the recombinant protein composition and acceptable excipients or adjuvants.

[0020] Preferably, the recombinant protein composition has a mass fraction of 0.001-0.3%.

[0021] More preferably, the recombinant protein composition has a mass fraction of 0.1%.

[0022] Preferably, the excipients or additives include at least one or more of thickeners, humectants, emollients, emulsifiers, pH adjusters, preservatives, chelating agents, and fragrances.

[0023] The thickener is one or more of the following: acrylate / C10-30 alkanol acrylate crosspolymer, ammonium acryloyldimethyl taurate / VP copolymer, xanthan gum, cellulose, sodium polyacrylate, carbomer, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer, gum arabic, and sodium acrylate copolymer.

[0024] The moisturizer is one or more of the following: glycerin, butylene glycol, propylene glycol, dipropylene glycol, 1,2-pentanediol, 1,2-hexanediol, 1,3-propanediol, sorbitol, ethoxydiethylene glycol, sugar isomers, panthenol, allantoin, trehalose, glyceryl polyether-26, betaine, sodium hyaluronate, and xylitol glucoside.

[0025] The emollient is one or more of the following: jojoba seed oil, phytosterols, guaiacol, cetearyl alcohol, stearyl alcohol, dimethicone, cyclopentamethicone, octyl polymethicone, dimethicone alcohol, dimethicone / vinyl dimethicone crosspolymer, polysiloxane-11, shea butter, dioctyl carbonate, squalane, pentaerythritol tetra(ethylhexanoate), hydrogenated olive oil decyl esters, cocoyl alcohol-caprylate / decyl ester, isononyl isononanoate, cetyl alcohol ethylhexanoate, and butylene glycol dicaprylate / didecyl ester.

[0026] The emulsifier is one or more of the following: glyceryl stearate SE, cetyl palmitate, polysorbate-20, C20-22 phosphate ester, C14-22 alcohol, cetearyl glucoside, arachidonic acid glucoside, PEG-100 stearate, PEG-40 stearate, hydrogenated lecithin, cetearyl olive oil ester, PEG-10 polydimethylsiloxane, sucrose polystearate, sodium stearoyl glutamate, polyglycerol-6 distearate, and glyceryl stearates.

[0027] The pH adjuster is one or more of aminomethylpropanol, sodium hydroxide, potassium hydroxide, arginine, and tromethamine.

[0028] The preservative is one or more of phenoxyethanol, methylparaben, propylparaben, p-hydroxyacetophenone, and chlorphenesin.

[0029] Preferably, the anti-wrinkle and firming skincare product comprises the following components by weight: disodium EDTA 0.01-0.04%, glycerin 3-8%, butylene glycol 4-10%, sodium hyaluronate 0.01-0.1%, hydroxyethyl acrylate / sodium acryloyl dimethyl taurate copolymer 0.1-0.6%, acrylate / C10-30 alkanol acrylate crosspolymer 0.05-0.2%, hydrogenated lecithin 0.1-0.3%, sodium stearoyl glutamate 0.1-0.5%, shea butter 1-5%, squalane 1.5-3.5%, isononyl isononanoate 2-4%, butylene glycol... The composition comprises: 1-3% dioctanoic acid / didecanoate, 0.5-2% cetearyl alcohol, 0.2-1% betaine alcohol, 0.5-1.5% hydrogenated olive oil decanol ester, 0.5-1.5% arachidonic acid glucoside, 0.5-2% polyglycerol-6 distearate, 2-5% polydimethylsiloxane, 0.2-5% polydimethylsiloxane / vinyl polydimethylsiloxane crosspolymer, 0.02-0.1% aminomethylpropanol, 0.2-0.8% p-hydroxyacetophenone, 0.5-1.5% 1,2-hexanediol, 0.001-0.5% of the recombinant protein composition of the present invention, and the balance being water.

[0030] Preferably, the dosage form of the anti-wrinkle and firming skin care product is one or more of the following: cream, lotion, mask, water, gel, oil, powder, aerosol, and freeze-dried.

[0031] Fourthly, the present invention provides a method for anti-wrinkle and firming skin, comprising applying the anti-wrinkle and firming skin care product described in the present invention.

[0032] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0033] The technical problem to be solved by this invention is to provide a recombinant protein composition for anti-wrinkle and skin-firming effects and its applications. The composition provided by this invention includes elastin, type XVII collagen, and fibronectin, and its unique ratio has been verified to have good anti-wrinkle and firming effects.

[0034] This invention uses elastin, type XVII collagen, and fibronectin in appropriate proportions to work together synergistically and comprehensively target the epidermis, achieving a three-dimensional anti-aging effect across the entire dermis, from the epidermis to the epidermal junction and back to the dermis. It has a significant effect on improving the signs of aging in the epidermis, dermis, and epidermal junction. Detailed Implementation

[0035] The technical solution of the present invention will be further described below with reference to specific embodiments. It should be noted that the following embodiments do not constitute a limitation on the scope of protection claimed by the present invention.

[0036] Unless otherwise specified, the raw materials, reagents or apparatus used in this invention are available from conventional commercial sources or can be obtained by existing known methods.

[0037] Table 1 shows the component ratios of the recombinant protein compositions in each example and comparative example.

[0038] Table 1: Composition of the Composition

[0039]

[0040] I. Example and Comparative Cell Efficacy Evaluation:

[0041] 1. Evaluation of the efficacy in promoting collagen gene expression

[0042] The experimental procedure was as follows: Human primary dermal fibroblasts were cultured in an incubator at 37°C with 5% CO2 and saturated humidity. After the cells reached over 80% confluence, they were digested and seeded into 12-well plates, and cultured for another 48 hours before testing. On the day of the experiment, the cells were divided into a blank control group, a UVA irradiation group, and a sample group. The UVA irradiation group and the sample group were first treated with UVA at 5 J / cm². 2Irradiation was applied, followed by further treatment with Examples 1 and Comparative Examples 1-6 for 24 hours. The supernatant was discarded, and each well was washed twice with 1 mL of pre-cooled phosphate buffer. Cell lysis buffer was then prepared using RNA extraction reagent. Total RNA was extracted from all lysis buffer samples, reverse transcribed into cDNA, and then the expression levels of collagen-related genes were detected using real-time quantitative PCR. Quantitative analysis was performed to obtain the gene expression levels of each group of cells.

[0043] 2. Evaluation of the efficacy in inhibiting the expression of aging proteins

[0044] The experimental procedure was as follows: Human primary dermal fibroblasts were cultured in an incubator at 37°C with 5% CO2 and saturated humidity. After the cells reached over 80% confluence, they were digested, seeded into 12-well plates, and cultured for another 48 hours for testing. On the day of the experiment, cells were divided into a blank group, a UVA irradiation group, and a sample group. The UVA irradiation group and the sample group were first irradiated with UVA at 5 J / cm², followed by further treatment with Example 1 and Comparative Examples 1-6, respectively, for 24 hours. The supernatant was discarded, and the cells were washed twice with 1 mL of pre-cooled phosphate buffer per well. Cell lysis buffer was then prepared using RNA extraction reagent. Total RNA was collected from the cells, reverse transcribed, and the expression levels of each gene were detected and quantified to obtain the gene expression levels of each group of cells.

[0045] 3. Evaluation of anti-inflammatory efficacy

[0046] The experimental procedure is as follows: Raw 264.7 mouse macrophages were cultured in DMEM containing 10% FBS. Cell Technology), maintained at 37°C and 5% CO2. When the cells reached 90% confluence, they were transplanted at a rate of 8 x 10... 5 Cells were seeded into 96-well plates at a concentration of [number] cells / mL. After 8 hours, the cells were treated with different concentrations of samples for 24 hours. Cell supernatants were collected and TNF-α and IL-6 were analyzed by ELISA. Each treatment was performed in triplicate. NT was culture medium only; the blank group was the LPS (lipopolysaccharide) treatment group; NC was LPS+PBS; the positive control was LPS+dexamethasone; and each sample treatment group was LPS+combination.

[0047] 4. Promotes the expression of genes related to moisturizing and repair.

[0048] The experimental procedure is as follows: In EpiLife containing 60 μM calcium... TM Normal human keratinocyte cell lines (NHEKs) were cultured in MEPI500CA medium (Thermo Fisher Scientific, USA). Cellular cells were stored at 37°C, 95% relative humidity, and 5% CO2 in a Thermo Fisher 160i incubator. When the cells reached 80-90% confluence, they were transferred from T75 flasks to 24-well plates, 50,000 cells per well. Cells were treated with different concentrations of O417 for 24 hours, washed once with cold PBS, and total RNA was extracted using the RNeasy Mini Kit (Qiagen). Total RNA was extracted and reverse transcribed into cDNA, and gene expression was detected by quantitative RT-PCR (qRT-PCR). NT represents culture medium only, and each sample group represents the example / comparative examples.

[0049] 5. Evaluation of efficacy in promoting cell proliferation

[0050] The experimental procedure is as follows: The proliferative effects of the compositions in the examples / comparative examples in Table 1 on human skin fibroblasts (HSF) were detected using the CCK8 assay. After culturing human skin fibroblasts for 24 hours, the compositions of the examples / comparative examples were added to the skin fibroblast culture medium at the specified concentration. NC served as a negative control without the addition of the compositions. After changing the culture medium and culturing for another 48 hours, CCK8 reagent was added and incubated for 2 hours. The OD was then measured using a microplate reader. 450 OD values ​​are used to calculate cell viability. A higher OD value indicates stronger metabolic activity and proliferative capacity of the cells.

[0051] Table 2: Effects of the composition on collagen gene expression in human primary dermal fibroblasts

[0052]

[0053]

[0054] Table 3: Effects of the composition on the expression of senescence-related genes in human primary dermal fibroblasts

[0055] Gene expression inhibition rate p16(CDKN2A) p21(CDKN1A) p53 Example 1 37％ 30％ 26％ Example 2 29％ 17％ 20％ Example 3 31％ 25％ 23％ Comparative Example 1 10％ / / Comparative Example 2 15％ 5％ / Comparative Example 3 / 15％ 10％ Comparative Example 4 20％ 25％ 5％ Comparative Example 5 25％ 27％ 10％ Comparative Example 6 28％ 20％ 18％

[0056] Table 4: Relative expression levels of TL-6 and TNF-α

[0057]

[0058]

[0059] Table 5: AQP1, AQP3, EPPK1

[0060] Experimental group name AQP1 expression level AQP3 expression level EPPK1 expression level NT (culture medium only) 100％ 100％ 100％ Example 1 169％ 153％ 190％ Example 2 155％ 148％ 180％ Example 3 157％ 140％ 175％ Comparative Example 1 105％ 107％ 155％ Comparative Example 2 110％ 117％ 140％ Comparative Example 3 135％ 120％ 160％ Comparative Example 4 130％ 125％ 163％ Comparative Example 5 145％ 130％ 168％ Comparative Example 6 147％ 135％ 165％

[0061] Table 6: OD450 values ​​of each experimental group

[0062]

[0063]

[0064] Experiments on the effects of human primary dermal fibroblast collagen gene expression showed that Example 1 had the best collagen synthesis effect (see Table 2), which increased the content of collagen and elastin in the dermis. Regarding the inhibitory effect on the expression of aging-related genes in human primary dermal fibroblasts, Example 1 showed the best inhibitory effect (see Table 3), which can reduce the rate of cell aging by regulating the expression of aging proteins. Experiments on the relative expression levels of inflammation-related mediators TNF-α and IL-6 showed that Example 1 had the best inhibitory effect (see Table 4), which can reduce skin aging problems induced by inflammatory factors. Experiments on the expression of moisturizing and repair-related genes showed that Example 1 had the best promoting effect (see Table 5), which has a good effect on repairing skin barrier function and increasing moisture content. Fibroblast proliferation experiments showed that Example 1 had the best cell proliferation effect (see Table 6), which has a significant effect on promoting cell proliferation.

[0065] II. Evaluation of the cosmetic efficacy of the composition in Example 1

[0066] The formulas of the skincare products containing anti-wrinkle and firming compositions for the experimental and control groups are shown in Table 7.

[0067] Table 7: Cosmetic Formulas Containing Anti-wrinkle and Firming Effects

[0068]

[0069]

[0070] The preparation method for this skincare product is as follows:

[0071] (1) Add phase A into the emulsifying pot, heat to 80-85℃, and stir until completely dissolved.

[0072] (2) Put phase B into the oil pot, heat to 80-85℃, and stir until completely dissolved.

[0073] (3) Slowly and evenly draw the raw materials in the oil pot into the emulsification pot, while increasing the emulsification and homogenization speed. After the drawing is completed, emulsify at 3000 rpm for 3-5 minutes.

[0074] (4) Cool down to 60℃, add C phase raw material, and homogenize appropriately for 1-2 minutes.

[0075] (5) Cool down to 45℃, add the D phase raw material, and stir evenly.

[0076] (6) Cool down to 37℃ and discharge the material after passing the inspection.

[0077] The experimental and control groups of products underwent human efficacy testing. The test items, experimental methods, and evaluation indicators are shown in Table 8.

[0078] Table 8: Test Items, Instruments, Methods and Indicators for Human Efficacy Evaluation

[0079]

[0080] The human efficacy test data are shown in Table 9.

[0081] Table 9: Evaluation Data of Various Human Functions

[0082]

[0083]

[0084] Human efficacy test data showed that the experimental group had better results than the control group in terms of the number of nasolabial folds, average wrinkle width, total wrinkle area, average wrinkle length, and wrinkle area percentage; the experimental group also had better elasticity (R2 and F4) values; better dermal density; better skin roughness (Sa); better skin hydration and mean TEWL values; and a smaller average redness area in the experimental group. In summary, the product containing the recombinant protein composition of Example 1 is superior to the control experiment in terms of anti-wrinkle and firming effects. The product containing the recombinant protein composition of Example 1 has significant advantages in multiple dimensions related to skin aging, including anti-wrinkle effect, skin elasticity, dermal density, epidermal hydration, transepidermal water loss, roughness, and redness.

[0085] The above description is merely a specific embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any person skilled in the art can conceive of various equivalent modifications or substitutions within the technical scope disclosed in the present invention, and these modifications or substitutions are all covered within the scope of protection of the present invention. Therefore, the scope of protection of the present invention should be determined by the scope of the claims.

Claims

1. A recombinant protein composition with anti-wrinkle and firming effects, characterized in that, The recombinant protein composition comprises the following components: elastin, type XVII collagen, and fibronectin; the mass ratio of elastin, type XVII collagen, and fibronectin is (3-500):(10-250):(15-250).

2. The recombinant protein composition according to claim 1, characterized in that, The mass ratio of elastin, type XVII collagen and fibronectin is (3-100):(10-50):(15-50).

3. The recombinant protein composition according to claim 1, characterized in that, The mass ratio of elastin, type XVII collagen and fibronectin is (1-2):(1-2):(1-2).

4. Use of the recombinant protein composition according to any one of claims 1 to 3 in the preparation of products for anti-wrinkle and / or skin firming.

5. An anti-wrinkle and firming skin care product comprising the recombinant protein composition of any one of claims 1 to 3 and acceptable excipients or adjuvants.

6. The anti-wrinkle and firming skincare product according to claim 5, characterized in that, The recombinant protein composition has a mass fraction of 0.001-0.3%.

7. The anti-wrinkle and firming skincare product according to claim 5, characterized in that, The excipients or additives include at least one or more of the following: thickeners, humectants, emollients, emulsifiers, pH adjusters, preservatives, chelating agents, and fragrances.

8. The anti-wrinkle and firming skincare product according to claim 5, characterized in that, The anti-wrinkle and firming skincare product comprises the following components by weight: disodium EDTA 0.01-0.04%, glycerin 3-8%, butylene glycol 4-10%, sodium hyaluronate 0.01-0.1%, hydroxyethyl acrylate / sodium acryloyl dimethyl taurate copolymer 0.1-0.6%, acrylate / C10-30 alkanol acrylate crosspolymer 0.05-0.2%, hydrogenated lecithin 0.1-0.3%, sodium stearoyl glutamate 0.1-0.5%, shea butter 1-5%, squalane 1.5-3.5%, isononyl isononanoate 2-4%, butylene glycol dimethyl ether... Caprylic / didecanoate 1-3%, cetearyl alcohol 0.5-2%, baicalein 0.2-1%, hydrogenated olive oil decyl ester 0.5-1.5%, arachidonic acid glucoside 0.5-1.5%, polyglycerol-6 distearate 0.5-2%, polydimethylsiloxane 2-5%, polydimethylsiloxane / vinyl polydimethylsiloxane crosspolymer 0.2-5%, aminomethylpropanol 0.02-0.1%, p-hydroxyacetophenone 0.2-0.8%, 1,2-hexanediol 0.5-1.5%, the recombinant protein composition of the present invention 0.001-0.5%, and the balance being water.

9. The anti-wrinkle and firming skincare product according to claim 5, characterized in that, The dosage form of the anti-wrinkle and firming skin care product is one or more of the following: cream, lotion, mask, water, gel, oil, powder, aerosol, and freeze-dried.

10. A method for anti-wrinkle and firming skin, comprising applying the anti-wrinkle and firming skin care product according to any one of claims 5 to 9.

Images